Ambrx, Inc.

The increasing global incidence of gastric cancer is a major factor driving the demand for gastric cancer diagnostics. The market is also being fueled by the rising prevalence of GERD and other stomach-related conditions, along with the growing number of stomach infections such as H. Pylori and gastroenteritis. Additionally, the surge in obesity and smoking, which are linked to the development of stomach cancer, are significant contributors to the market's growth during the forecast period from 2024 to 2030. LAS VEGAS, Sept. 3, 2024 /PRNewswire/ -- DelveInsight's Gastric Cancer Diagnostics Market Insights report provides the current and forecast market analysis, individual leading gastric cancer diagnostics companies' market shares, challenges, gastric cancer diagnostics market drivers, barriers, trends, and key market gastric cancer diagnostics companies in the market. Key Takeaways from the Gastric Cancer Diagnostics Market Report As per DelveInsight estimates, North America is anticipated to dominate the global gastric cancer diagnostics market during the forecast period. In the product type segment of the gastric cancer diagnostics market, the reagents & kits category generated a significant revenue share in the gastric cancer diagnostics market in 2023. Notable gastric cancer diagnostics companies such as Abbott, BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Pillar Biosciences Inc., Hologic, Inc., CD Genomics, Natera, Inc., Biodesix, Illumina, Inc., Quest Diagnostics, Agilent Technologies, Inc., FUJIFILM Holdings Corporation, NeoGenomics Laboratories, Guardant Health, Myriad Genetics, Inc., Invitae Corporation, Danaher, and several others, are currently operating in the gastric cancer diagnostics market. In March 2024, AI Medical Service Inc. announced that it had launched gastroAI-model G, an AI-based endoscopic diagnostic support device that operates within the stomach. The diagnostic device operates by scanning for potential lesions, utilizing images derived from the video processor of the endoscopy system. Upon determining that a lesion appears suspicious for early gastric cancer and requires additional evaluation, the program notifies the physician and offers diagnostic support by presenting a highlighted area within the endoscopic display. In November 2023, Dedalus Group in collaboration with Ibex Medical Analytics, announced the launch of a fully integrated AI-powered digital pathology solution for gastric cancer diagnosis. In August 2023, Mirxes Pte Ltd announced that its flagship product GASTROClear, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). It is a molecular blood test for the early detection of gastric cancer that helps to cure cancer with affordable treatment. To read more about the latest highlights related to the gastric cancer diagnostics market, get a snapshot of the key highlights entailed in the Global Gastric Cancer Diagnostics Market Report Gastric Cancer Diagnostics Overview Gastric cancer, or stomach cancer, is typically diagnosed through a combination of clinical evaluation, imaging techniques, and tissue biopsy. The diagnostic process often begins with a patient's history and physical examination, focusing on symptoms like persistent indigestion, weight loss, and abdominal pain. Imaging studies, such as upper gastrointestinal endoscopy, are crucial as they allow direct visualization of the stomach lining. During an endoscopy, a flexible tube with a camera is inserted through the mouth into the stomach, enabling doctors to identify suspicious lesions or tumors. Additional imaging techniques, such as computed tomography (CT) scans or positron emission tomography (PET) scans, may be used to determine the extent of the cancer and to detect possible metastasis to other organs. Confirming a diagnosis of gastric cancer requires a biopsy, where tissue samples are taken during an endoscopy and examined under a microscope for cancerous cells. Histopathological analysis of the biopsy helps determine the type and grade of the cancer, which is critical for guiding treatment options. Molecular testing on the biopsy sample can also identify specific genetic mutations or protein expressions, such as HER2, which may influence targeted therapy decisions. Blood tests for tumor markers like carcinoembryonic antigen (CEA) and CA 19-9 are sometimes used to support diagnosis or monitor treatment response, although these markers are not specific to gastric cancer. Early and accurate diagnosis is essential in improving the prognosis and survival rates for patients with gastric cancer. Gastric Cancer Diagnostics Market Insights In 2023, North America held the largest share of the gastric cancer diagnostics market. This dominance is attributed to the increasing prevalence of gastric cancer and related stomach diseases, along with the region's growing geriatric population and advancements in early cancer detection technologies. Data from the American Cancer Society, published in January 2024, predicts approximately 26,890 new cases of stomach cancer in the United States for 2024, with 16,160 cases among men and 10,730 among women. Stomach cancer accounts for about 1.5% of all new cancer diagnoses annually in the country. The higher incidence of gastric cancer among older adults is linked to age-related risk factors such as stomach infections and gastroesophageal reflux disease (GERD). As a result, the expanding elderly population is expected to drive the growth of the gastric cancer diagnostics market in the region. In March 2024, Ibex Medical Analytics launched Galen, an AI-powered diagnostic platform that offers accurate cancer diagnoses, reduces manual tasks, and is used for diagnosing gastric cancer, H. pylori, and other gastric lesions like adenoma and low-grade dysplasia. This increase in R&D activities by major players to develop advanced diagnostic solutions is expected to further boost the North American gastric cancer diagnostics market. To know more about why North America is leading the market growth in the gastric cancer diagnostics market, get a snapshot of the Gastric Cancer Diagnostics Market Outlook Gastric Cancer Diagnostics Market Dynamics The gastric cancer diagnostics market is evolving rapidly, driven by technological advancements, increasing awareness, and a growing focus on early detection. Gastric cancer, which remains one of the leading causes of cancer-related mortality worldwide, particularly in Asia and Eastern Europe, has led to a pressing need for improved diagnostic methods. Traditional diagnostic techniques like endoscopy and biopsy are now being complemented and, in some cases, replaced by innovative, non-invasive technologies such as liquid biopsy, molecular diagnostics, and advanced imaging techniques. These new modalities offer the potential for earlier detection, more accurate staging, and better monitoring of disease progression, which is critical for improving patient outcomes. A significant dynamic in the market is the integration of molecular diagnostics, including next-generation sequencing (NGS), which allows for the detection of specific genetic mutations and biomarkers associated with gastric cancer. These advancements are not only enhancing the precision of diagnosis but also paving the way for personalized medicine, where treatment can be tailored based on an individual's genetic profile. The push towards personalized medicine is further fueling the demand for diagnostic tools that can provide comprehensive genomic data, leading to an increase in partnerships between diagnostic companies and pharmaceutical firms aiming to develop targeted therapies. Furthermore, the rise of artificial intelligence and machine learning in diagnostics is another key trend shaping the gastric cancer diagnostics market. AI and ML are being integrated into imaging and pathology tools to improve the accuracy of cancer detection and reduce the chances of human error. These technologies can analyze large datasets, identify patterns, and make predictions that can assist clinicians in making more informed decisions. The growing adoption of AI-driven diagnostic platforms is expected to enhance the efficiency of gastric cancer screening programs and reduce the time required for diagnosis. The market is also influenced by the increasing prevalence of gastric cancer in aging populations, particularly in regions with high incidence rates. This demographic shift is expected to drive the demand for more accessible and cost-effective diagnostic solutions. Governments and healthcare organizations in these regions are investing in public health initiatives aimed at improving cancer screening and early detection rates, which is likely to further boost the market for diagnostic products and services. However, the market faces challenges, such as high costs associated with advanced diagnostic technologies and the need for specialized expertise to interpret complex diagnostic results. Additionally, disparities in healthcare infrastructure and access to advanced diagnostics between developed and developing regions may limit market growth in certain areas. Despite these challenges, the overall outlook for the gastric cancer diagnostics market remains positive, with continuous innovations and increasing emphasis on early detection poised to significantly impact the landscape in the coming years. Get a sneak peek at the gastric cancer diagnostics market dynamics @ Gastric Cancer Diagnostics Market Dynamics Analysis Gastric Cancer Diagnostics Market Assessment Gastric Cancer Diagnostics Market Segmentation Gastric Cancer Diagnostics Market Segmentation By Product Type: Instruments, Reagents & Kits Gastric Cancer Diagnostics Market Segmentation By Test Test: Imaging Test [Upper Endoscopy, Barium Swallow/X-Rays, CT Scan, Laparoscopy, MRI, Stomach Ultrasound, and Others], Laboratory Test [Biopsy, Blood Test, and Others] Gastric Cancer Diagnostics Market Segmentation By End Users: Hospitals, Diagnostic Laboratories, Academic & Research Institutes, Diagnostic Centers, and Others Gastric Cancer Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the gastric cancer diagnostics market are set to emerge as the trendsetter explore @ Gastric Cancer Diagnostics Companies Table of Contents Interested in knowing the gastric cancer diagnostics market by 2030? Click to get a snapshot of the Gastric Cancer Diagnostics Market Trends Related Reports Gastric Cancer Market Gastric Cancer Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key gastric cancer companies, including Hanmi Pharmaceuticals, Merck, Minneamrita Therapeutics, Taiho Pharmaceuticals, Bayer, among others. Gastric Cancer Pipeline Gastric Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key gastric cancer companies, including BeiGene, Linton Pharm Co. Ltd., RAPT Therapeutics, Leap Therapeutics, Idience, Bolt Biotherapeutics, Hubro Therapeutics, Immunocore, Ambrx, Hangzhou DAC Biotech, Beijing Immunoah Pharma Tech, Base Therapeutics, Nanjing KAEDI Biotech, HiberCell, Transcenta Holding, Suzhou Zelgen Biopharmaceuticals, Daiichi Sankyo, Ipsen, Alligator Bioscience, Bristol Myers Squibb, Jiangsu Hengrui Medicine, Shanghai Junshi Biosciences, ImmunoACT, among others. Gastroesophageal Reflux Disease Market Gastroesophageal Reflux Disease Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key GERD companies, including Phathom Pharmaceuticals, Inc., Microbiome Health Sciences, Takeda, Braintree Laboratories, AstraZeneca, among others. Gastroesophageal Reflux Disease Pipeline Gastroesophageal Reflux Disease Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GERD companies, including Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

Pictured: ADCs and money/Taylor Tieden for BioSpace For the first time, the global market size of antibody drug conjugates (ADCs) exceeded $10 billion last year, at an estimated $11.29 billion, according to Grand View Research. This trend is expected to continue for the next few years, with ADCs reaching an estimated worth of nearly $30 billion by 2028, according to the market intelligence firm Evaluate. Neha Rathod Godbole, a senior analyst at Vantage Market Research, said that analysts foresee the field’s current momentum persisting, as it is supported by a robust pipeline of ADC candidates and expanding therapeutic applications. “The ADC market is on a trajectory of rapid growth, and this expansion is driven by the escalating incidence of cancer worldwide and the growing demand for targeted therapies that offer higher efficacy and fewer side effects compared to traditional treatments,” Godbole said. “Recent approvals of ADCs, such as Enhertu for breast cancer, underscore their potential to transform oncology treatment landscapes.” She noted that the ADC sector is also experiencing rising investment and strategic collaborations. “Major pharmaceutical companies are increasingly partnering with biotech firms to leverage cutting-edge technologies and expedite the development of next-generation ADCs,” Godbole said. As examples, she pointed to the recent partnership between AstraZeneca and Daiichi Sankyo on the development of Enhertu, as well as a strategic partnership between Caris Life Sciences and Merck KGaA. “These alliances are not only fostering innovation but also enhancing the scalability and commercial viability of ADC products,” Godbole explained. The ADC market does face several challenges, she noted, including high development costs, complex manufacturing processes and the need for robust clinical validation, but she added that ongoing research and technological advancements are mitigating these challenges. “With a strong pipeline of ADCs in various stages of clinical development, we anticipate a steady flow of new approvals in the coming years,” Godbole said. “The successful clinical trials of novel ADCs targeting diverse cancer types, such as non-Hodgkin lymphoma and ovarian cancer, indicate a broadening of the therapeutic scope of ADCs.” Here are five major deals from the first half of 2024 that caught our attention: 1. Johnson & Johnson/Ambrx J&J kicked off the year by announcing that it was going to purchase Ambrx for $28 a share, amounting to a total of about $2 billion. Ambrx specialized in developing ADCs, and J&J intends to work with Ambrx researchers to accelerate the Phase 1/2 APEX-01 study of ARX517 for advanced prostate cancer, along with a pipeline of novel product candidates. 2. Genmab/ProfoundBio Genmab will acquire ProfoundBio, a privately owned biotech company, for $1.8 billion in cash, Genmab announced in April. The Seattle-based biotech is developing drugs to treat ovarian and endometrial cancers, and the deal “reflects strategic consolidation in the ADC space, leveraging ProfoundBio’s expertise and pipeline to strengthen its competitive position in oncology therapeutics,” Godbole said. This acquisition gives Genmab access to ProfoundBio’s portfolio of ADCs, three of which are currently in clinical trials. 3. Ipsen/Sutro Biopharma Also in early April, Ipsen and Sutro Biopharma made public a $900 million deal for global rights to development and commercialization of Sutro’s STRO-003, an anticancer ADC that is completing the final stages of preclinical development. This is the first ADC candidate in Ipsen’s portfolio, and the company will be responsible for moving the product to a Phase I clinical trial, including submission of the Investigational New Drug (IND) application. 4. Biotheus/Hansoh In March, Biotheus, a clinical-stage company focused on developing therapeutics for oncology and inflammatory disease, and Hansoh Pharmaceutical Group announced an expansion of their partnership into ADCs. The partnership between the two China-based companies involves RMB 5 billion ($694.8 million) in upfront and potential payments to Biotheus. Biotheus will grant Hansoh a license to use its Phase I antibody PM1080/HS-20117 to develop ADC therapeutics. 5. Merck/Abceutics Merck has bought biotech startup Abceutics for $208 million, according to an April announcement from the University at Buffalo. The company’s core technology, payload-binding selectivity enhancers (PBSEs), was licensed from the university, and reduces the risk of side effects when given along with ADCs, according to the announcement. The specific breakdown of the deal’s overall potential value was not discussed by either company, but the total includes Merck’s upfront payment as well as milestones for the candidates. Roxanne Nelson is a registered nurse and an award-winning medical writer who has written for many major news outlets and publications.

This is the second bispecific antibody deal Johnson & Johnson has signed in as many weeks, after the May 16 deal to acquire Proteologix for $850 million. Not satisfied with just one new immunology deal this month, Johnson & Johnson is plunking down $1.25 billion in cash to scoop up rights to Numab Therapeutics’ phase 2-ready atopic dermatitis bispecific antibody. The healthcare giant is picking up NM26, which is on the cusp of entering midstage trials. The therapy is currently in development for atopic dermatitis (AD), but J&J has its sights set on other inflammatory skin diseases. Details of the transaction in a Tuesday release were slim, besides the eye-popping all-cash payment of $1.25 billion to be paid to Numab for global rights to the drug. J&J is not buying the biotech itself—just the drug rights. Closing is expected in the second half of the year. But Numab investor Novo Holdings said the deal involves the acquisition of Yellow Jersey Therapeutics, a subsidiary of Numab. Yellow Jersey contains all the assets relating to NM26.  "Our initial investment in Numab was based on our strong conviction in the underlying technology of multi-specific antibodies. The management and the board took the strategic decision to focus the company on NM26, an IL4/IL31 bi-specific antibody for use in auto-immune disease, with atopic dermatitis as the lead indication. This decisiveness paid off, with the program delivering exciting early data in patients leading to the acquisition," Novo Holdings Partner Michael Bauer said in a Tuesday release.  Numab will continue work on its pipeline, which includes inflammatory assets in preclinical development and a phase 1 therapy for solid tumors.  NM26 targets the IL-4R alpha subunit (IL-4Rα) and IL-31, which are associated with skin inflammation and itch, respectively. J&J believes the therapy could have wide impact on other diseases driven by these pathways. “Our investment in differentiated bispecifics is the next chapter in our impactful immunology legacy. It reinforces our commitment to address unmet medical needs by leveraging patient insights and our deep disease expertise,” said Candice Long, worldwide vice president of immunology at J&J, in a Tuesday statement. This is the second bispecific antibody deal J&J has signed in as many weeks, after the May 16 deal to acquire Proteologix for $850 million. That deal involved a collection of bispecific immunology meds, including one that is poised to enter phase 1. That asset, called PX128, is a bispecific antibody targeting both IL-13 and the IL-2-like cytokine TSLP for patients with AD and severe asthma. J&J has been on the hunt to bolster its immunology roster after a $750 million bolt-on deal with XBiotech in 2019 failed to deliver. The pharma nixed the asset from that deal, an antibody called bermekimab, after ending development in eczema. Elsewhere, J&J’s business development team has been busy, acquiring ADC biotech Ambrx for $2 billion in January.